Angiex presented preclinical data for AGX101 at The AACR Special Conference In Cancer Research: Tumor-Body Interactions: The Roles of Micro- and Macroenvironment in Tumor Heterogeneity, Metastasis, and Therapy Response, held in Boston, Massachusetts on November 17-20, 2024.
The poster presentation, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial,” was presented by Angiex Chief Medical Officer Glen Weiss, M.D., on behalf of his co-authors: Principal Investigators I. Ismael Rodriguez Rivera, M.D. of NEXT Oncology; Meredith S. Pelster, M.D. of Sarah Cannon Research Institute; and Angiex founders Paul and Shou-Ching Jaminet.
The abstract has been published in the AACR journal Cancer Research, here. Citation: Ildefonso Ismael Rodriguez Rivera, Meredith S. Pelster, Shou-Ching Jaminet, Paul Jaminet, Glen J. Weiss. AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl):Abstract nr C047.
Download the poster here:
angiex-aacr-poster-nov2024.pdf
Key insights from the poster
TM4SF1: a new target for oncology therapies
TM4SF1 has emerged as a promising target for antibody-drug conjugate (ADC) therapies. Its high expression in most solid tumors and a novel internalization pathway enabling direct drug delivery to the nucleus make it an ideal candidate for targeted treatments.
AGX101’s dual mechanism of action
Angiex’s first-in-class ADC, AGX101, combines two mechanisms: killing tumor cells directly and attacking the tumor vasculature to deprive cancers of their blood supply. This dual approach represents a novel direction for anti-angiogenic therapy.
Preclinical success
AGX101 demonstrated effectiveness across diverse preclinical models, highlighting its potential to address a wide range of solid tumors. These findings support its ongoing clinical evaluation.
Leadership in TM4SF1-directed ADCs
Angiex is leading the field in TM4SF1-directed ADCs, with AGX101 currently dosing patients in a first-in-human clinical trial.